Uncontrolled hypertension is an important clinical problem and is associated with considerable morbidity and mortality. A new report from the SPYRAL HTN-OFF MED researchers, which describes the use of renal denervation in patients with uncontrolled hypertension, might reignite enthusiasm for this technique, while a first-in-human description of endovascular baroreflex amplification from the CALM-FIM_EUR investigators highlights the potential of this new approach to inhibit sympathetic activity.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioral, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease study 2016. Lancet 390, 1345–1422 (2017).
de Jager, R. L. et al. Impact of medication adherence on the effect of renal denervation: the SYMPATHY trial. Hypertension 69, 678–684 (2017).
Gupta, P. et al. Risk factors for nonadherence to antihypertensive treatment. Hypertension 69, 1113–1120 (2017).
Townsend, R. R. et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet http://dx.doi.org/10.1016/S0140-6736(17)32281-X (2017).
Spiering, W. et al. Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. Lancet http://dx.doi.org/10.1016/S0140-6736(17)32337-1 (2017).
Vink, E. E. et al. Limited destruction of renal nerves after catheter-based renal denervation: results of a human case study. Nephrol. Dial Transplant. 29, 1608–1610 (2014).
de Jager, R. L. et al. Renal denervation in hypertensive patients not on blood pressure lowering drugs. Clin. Res. Cardiol. 105, 755–762 (2016).
Chow, C. K. et al. Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. Lancet 389, 1035–1042 (2017).
de Beus, E. et al. Sympathetic activation secondary to chronic kidney disease: therapeutic target for renal denervation? J. Hypertens. 32, 1751–1761 (2014).
de Jager, R. L. et al. Catheter based renal denervation as therapy for chronic severe kidney related pain. Nephrol. Dial Transplant. http://dx.doi.org/10.1093/ndt/gfx086 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P.J.B. has received research grants from Medtronic, ZonMw and Nierstichting Nederland. The grants were paid to the institution. M.L.B. declares no competing interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Blankestijn, P., Bots, M. Device therapy for uncontrolled hypertension: new approaches to an old problem. Nat Rev Nephrol 13, 725–726 (2017). https://doi.org/10.1038/nrneph.2017.150
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2017.150
